JANUS HENDERSON GROUP (JHG) Company Report

Halper Sadeh LLC is investigating Janus Henderson Group plc (NYSE: JHG) for potential violations of federal securities laws and/or breaches of fiduciary duties.
The investigation concerns JHG's sale to Trian Fund Management and General Catalyst for $49.00 per share in cash.
The firm is encouraging Janus shareholders to contact them to discuss their legal rights and options, potentially seeking increased consideration or additional disclosures.

6 days ago

Press Release

Janus Henderson Group plc Reports Q4 and Full-Year 2025 Results, Announces Proposed Merger, and Suspends Dividend

JHG

Earnings

M&A

Dividends

Janus Henderson Group plc reported Q4 2025 diluted EPS of US$2.62 and adjusted diluted EPS of US$2.01, with Assets Under Management (AUM) growing 30% year over year to US$493 billion as of December 31, 2025.
The company achieved breakeven net flows in Q4 2025 and US$56.5 billion of net inflows for the full year 2025.
Janus Henderson has entered into a definitive merger agreement to be acquired by an investor group led by Trian Fund Management, L.P. and General Catalyst Group Management, LLC.
As a result of the proposed merger, the company is suspending the payment of its regular quarterly dividend.
Additionally, Janus Henderson announced a definitive agreement to acquire Richard Bernstein Advisors (RBA) to enhance its model portfolio and separately managed account offerings.

8 days ago

8-K

ProMIS Neurosciences Announces Private Placement Financing

JHG

ProMIS Neurosciences Inc. has entered into a securities purchase agreement for a private investment in public equity (PIPE) financing of up to approximately $175 million.
The financing comprises common shares, common share warrants, and pre-funded warrants.
The PIPE financing is co-led by Janus Henderson and Ally Bridge Group, with participation from other institutional and accredited investors, as well as ProMIS's CEO, management team, and Board of Directors.
The upfront gross proceeds are anticipated to be approximately $75 million, with an additional approximately $100 million if the common share warrants and pre-funded warrants are fully exercised for cash.
The proceeds are expected to extend ProMIS's cash runway into 2028 and enable the completion of its landmark Phase 1b Alzheimer's disease clinical study. The financing is expected to close on February 3, 2026.

8 days ago

Press Release

Janus Henderson Group PLC Announces Q4 and Full-Year 2025 Results

JHG

Earnings

Revenue Acceleration/Inflection

Janus Henderson Group PLC reported Total Assets Under Management (AUM) of $493.2 billion at the end of Q4 2025.
The company recorded net flows of $0.0 billion in Q4 2025, contributing to $56.5 billion in net flows for the full year 2025.
U.S. GAAP diluted EPS was $2.62 for Q4 2025 and $5.23 for the full year 2025.
Total revenue reached $1,142.3 million in Q4 2025 and $3,097.3 million for the full year 2025.
Investment performance remained solid, with 65% of AUM outperforming its benchmark over 3, 5, and 10 years as of December 31, 2025.

8 days ago

Presentation

Janus Henderson to Acquire Richard Bernstein Advisors

JHG

M&A

New Projects/Investments

Takeover Bid

Janus Henderson has agreed to acquire Richard Bernstein Advisors (RBA), a research-driven macro investment manager that oversees approximately $20 billion in client assets.
The acquisition is expected to significantly strengthen Janus Henderson’s model portfolio and separately managed account (SMA) offerings, positioning the firm among the top 10 model-portfolio providers in North America.
Richard Bernstein will join Janus Henderson as Global Head of Macro & Customized Investing and has signed a multi-year agreement to lead RBA’s next phase of growth.
The transaction is expected to close in the second quarter of 2026, although financial terms were not disclosed.
This acquisition comes as Janus Henderson itself is set to be taken private following a $7.4 billion buyout by Trian and General Catalyst.

Jan 23, 2026, 6:20 PM

WSJ

Janus Henderson to Acquire Richard Bernstein Advisors

JHG

M&A

New Projects/Investments

Janus Henderson Group (JHG) has entered into a definitive agreement to acquire Richard Bernstein Advisors (RBA), a research-driven, macro multi-asset investment manager.
RBA oversees approximately $20 billion in client assets as of January 16, 2026, and the acquisition is expected to position Janus Henderson as a leading model portfolio and separately managed account (SMA) provider.
The transaction is anticipated to close in Q2 2026.

Jan 23, 2026, 2:00 PM

Press Release

Janus Henderson-backed Caldera Therapeutics Launches with $112.5 Million and Doses First Subjects in Phase 1 Trial

JHG

New Projects/Investments

Caldera Therapeutics launched with $112.5 million in total capital raised, including a $37.5 million Series A-1 funding round in which Janus Henderson Investors participated.
The company announced that the first subjects have been dosed in a Phase 1 trial for its lead program, CLD-423.
CLD-423 is a first-in-class bispecific antibody designed to treat inflammatory bowel disease (IBD) and other immunologic and inflammatory diseases.

Jan 14, 2026, 12:00 PM

Press Release

Janus Henderson to Report Q4 and Full-Year 2025 Results Amidst Pending Acquisition

JHG

Earnings

Guidance Update

M&A

Janus Henderson Group (JHG) will announce its fourth quarter and full-year 2025 results pre-market open on Friday, January 30, 2026.
The company entered into a definitive merger agreement on December 22, 2025, to be acquired by an investor group led by Trian Fund Management, L.P. and General Catalyst Group Management, LLC.
Due to the pending Proposed Transaction, Janus Henderson will not hold conference calls or live webcasts to discuss its financial results and is suspending its financial guidance for full-year 2026.
The Proposed Transaction is expected to close in mid-2026, subject to customary closing conditions including regulatory approvals, client consents, and shareholder approval.

Jan 13, 2026, 2:00 PM

Press Release

Ottimo Pharma Announces FDA Clearance for OTP-01 and Dosing of First Patient

JHG

Product Launch

New Projects/Investments

Ottimo Pharma received FDA clearance for its Investigational New Drug (IND) application for OTP-01, a first-in-class, dual-paratopic, anti-PD-1/VEGFR2 antibody.
The first patient has been dosed in a broad Phase I/IIA study for OTP-01, which is enrolling patients in the US and Australia.
OTP-01 is designed as a next-generation antibody with potent PD-1 inhibition and unique VEGFR2 receptor inhibitory properties, aiming to be a backbone therapy for various solid tumors.
All manufacturing of OTP-01 is occurring solely in the US.

Jan 7, 2026, 6:15 PM

Press Release

Janus Henderson Group plc Announces Merger Agreement

JHG

M&A

Takeover Bid

Janus Henderson Group plc (JHG) has entered into an Agreement and Plan of Merger with Jupiter Company Limited and Jupiter Merger Sub Limited, dated December 21, 2025.
Under the terms of the merger, each ordinary share of JHG (excluding certain shares) will be converted into the right to receive $49.00 in cash.
The transaction is expected to close in mid-2026 and is subject to customary closing conditions, including receipt of applicable regulatory approvals, client consents, and approval by Janus Henderson’s shareholders.
The acquisition will be funded in part by investment vehicles managed by Trian and General Catalyst, with additional financing from global investors such as Qatar Investment Authority, Sun Hung Kai & Co. Limited, and MassMutual. Trian and related parties will also roll over their currently held shares.